Probiotics in inflammatory bowel disease--therapeutic rationale and role.

Hdl Handle:
http://hdl.handle.net/10147/208958
Title:
Probiotics in inflammatory bowel disease--therapeutic rationale and role.
Authors:
Shanahan, Fergus
Affiliation:
Alimentary Pharmabiotic Centre, Department of Medicine, Clinical Science, Building, Cork University Hospital, University College Cork, National University , of Ireland, Wilton, Cork, Ireland. F.Shananhan@ucc.ie
Citation:
Adv Drug Deliv Rev. 2004 Apr 19;56(6):809-18.
Journal:
Advanced drug delivery reviews
Issue Date:
3-Feb-2012
URI:
http://hdl.handle.net/10147/208958
DOI:
10.1016/j.addr.2003.11.003
PubMed ID:
15063591
Abstract:
The intestinal flora has a conditioning effect on intestinal homeostasis, delivering regulatory signals to the epithelium, the mucosal immune system and to the neuromuscular activity of the gut. Beneficial metabolic activities of the enteric flora include nutrient production, metabolism of dietary carcinogens, conversion of prodrugs to active drugs. However, increasing evidence suggests that some components of the enteric flora are essential ingredients in the pathogenesis of inflammatory bowel disease (IBD); this has prompted interest in therapeutic manipulation of the flora with probiotics. Probiotics are biologic control agents-described as live microbial food supplements which confer a health benefit beyond inherent basic nutrition. Multiple potential beneficial effects have been attributed to the probiotic use of lactic acid bacteria, bifidobacteria and other non-pathogenic commensals. At present, much of the promise of probiotics remains outside the realm of evidence-based medicine and awaits the results of prospective trials, now underway. No reliable in vitro predictors of in vivo efficacy of putative probiotics have been identified. Rigorous comparisons of probiotic performance have not been performed and the suitability of a given probiotic for different individuals is largely unexplored. Notwithstanding, an improved understanding of the normal commensal flora and host-flora interactions has the potential to open up new therapeutic strategies for inflammatory disorders of the gut.
Language:
eng
MeSH:
Animals; Humans; Inflammatory Bowel Diseases/*drug therapy/*microbiology; Probiotics/*therapeutic use
ISSN:
0169-409X (Print); 0169-409X (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorShanahan, Fergusen_GB
dc.date.accessioned2012-02-03T15:08:29Z-
dc.date.available2012-02-03T15:08:29Z-
dc.date.issued2012-02-03T15:08:29Z-
dc.identifier.citationAdv Drug Deliv Rev. 2004 Apr 19;56(6):809-18.en_GB
dc.identifier.issn0169-409X (Print)en_GB
dc.identifier.issn0169-409X (Linking)en_GB
dc.identifier.pmid15063591en_GB
dc.identifier.doi10.1016/j.addr.2003.11.003en_GB
dc.identifier.urihttp://hdl.handle.net/10147/208958-
dc.description.abstractThe intestinal flora has a conditioning effect on intestinal homeostasis, delivering regulatory signals to the epithelium, the mucosal immune system and to the neuromuscular activity of the gut. Beneficial metabolic activities of the enteric flora include nutrient production, metabolism of dietary carcinogens, conversion of prodrugs to active drugs. However, increasing evidence suggests that some components of the enteric flora are essential ingredients in the pathogenesis of inflammatory bowel disease (IBD); this has prompted interest in therapeutic manipulation of the flora with probiotics. Probiotics are biologic control agents-described as live microbial food supplements which confer a health benefit beyond inherent basic nutrition. Multiple potential beneficial effects have been attributed to the probiotic use of lactic acid bacteria, bifidobacteria and other non-pathogenic commensals. At present, much of the promise of probiotics remains outside the realm of evidence-based medicine and awaits the results of prospective trials, now underway. No reliable in vitro predictors of in vivo efficacy of putative probiotics have been identified. Rigorous comparisons of probiotic performance have not been performed and the suitability of a given probiotic for different individuals is largely unexplored. Notwithstanding, an improved understanding of the normal commensal flora and host-flora interactions has the potential to open up new therapeutic strategies for inflammatory disorders of the gut.en_GB
dc.language.isoengen_GB
dc.subject.meshAnimalsen_GB
dc.subject.meshHumansen_GB
dc.subject.meshInflammatory Bowel Diseases/*drug therapy/*microbiologyen_GB
dc.subject.meshProbiotics/*therapeutic useen_GB
dc.titleProbiotics in inflammatory bowel disease--therapeutic rationale and role.en_GB
dc.contributor.departmentAlimentary Pharmabiotic Centre, Department of Medicine, Clinical Science, Building, Cork University Hospital, University College Cork, National University , of Ireland, Wilton, Cork, Ireland. F.Shananhan@ucc.ieen_GB
dc.identifier.journalAdvanced drug delivery reviewsen_GB
dc.description.provinceMunster-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.